---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108854"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:45:17.245219+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas

## Summary
- Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.
- Net income $5.2M ($0.02 diluted) vs net loss $2.9M ($0.45 loss) in Q2 2024; derivative gain of $6.5M pre-tax.
- CNSide CSF assay launched in Texas in Aug 2025; TAM estimated $6B; additional states planned late 2025-2026.
- REYOBIQ dose optimization trial started; FDA IND clearance for pediatric high-grade glioma and ependymoma.
- Received $1.6M advance from $17.6M CPRIT grant; added industry veteran Kyle Guse to Board of Directors.

## SEC filing metadata
- accession: 0000950170-25-108854
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/0000950170-25-108854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/pstv-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108854
- JSON: https://secwatch.observer/filing/0000950170-25-108854.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.